New combo shot shows promise for weight loss in chinese adults
NCT ID NCT05996848
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new weekly injection called CagriSema, which combines two drugs (cagrilintide and semaglutide), to help Chinese adults with obesity or overweight lose weight. About 300 participants received either CagriSema, semaglutide alone, or a placebo for around one year. The main goals were to see how much weight they lost and how many achieved at least a 5% reduction in body weight.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CagriSema (cagrilintide and semaglutide combination)
What this could lead to
If successful, this could provide a new weekly injection option for significant weight loss in Chinese adults with obesity or overweight.
What could go wrong
This is a Phase 3 trial, but results may not apply to all populations. Side effects from the drugs (like nausea or gastrointestinal issues) are possible, and the long-term safety is still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Central Hospital of Minhang District, Shanghai-Endocrinology
Shanghai, Shanghai Municipality, 201199, China
-
Central Hospital of Minhang District-Endocrinology
Shanghai, Shanghai Municipality, 201199, China
-
Changzhou No.2 People's Hospital
Changzhou, Jiangsu, 213003, China
-
Chinese People's Liberation Army General Hospital-Endocrinology
Beijing, Beijing Municipality, 100853, China
-
Chongqing University Three Gorges Hospital
Chongqing, Chongqing Municipality, 404000, China
-
Fujian Medical University Union Hospital-Endocrinology
Fuzhou, Fujian, 350001, China
-
General Hospital of Tianjin Medical University
Tianjin, Tianjin Municipality, 300052, China
-
General Hospital of Tianjin Medical University-Endocrinology
Tianjin, Tianjin Municipality, 300052, China
-
Hengshui People's Hospital (Harrison International Peace Hospital)-Endocrinology
Hengshui, Hebei, 053000, China
-
Huaihe Hospital of Henan University
Kaifeng, Henan, 475000, China
-
Huaihe Hospital of Henan University-Endocrinology
Kaifeng, Henan, 475000, China
-
Huashan Hospital Fudan University
Shanghai, Shanghai Municipality, 200040, China
-
Huashan Hospital Fudan University
Jingan/Shanghai, 200040, China
-
Huizhou Central People's Hospital-Endocrinology
Huizhou, Guangdong, 516001, China
-
Jinan Central Hospital
Ji'nan, Shandong, 250013, China
-
Jinan Central Hospital
Jin'an, Shandong, 250013, China
-
Jinan Central Hospital
Jinan, Shandong, 250013, China
-
Shanghai Pudong New Area People's Hospital-Endocrinology
Shanghai, Shanghai Municipality, 201200, China
-
Suzhou Municipal Hospital-Endocrinology
Suzhou, Jiangsu, 215002, China
-
The Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, 212001, China
-
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, 221002, China
-
The First Affiliated Hospital of Henan University of Science and Technology-Endocrinology
Luoyang, Henan, 471003, China
-
The First Affiliated Hospital of Henan university of Science
Luoyang, Henan, 471003, China
-
The First Affiliated Hospital of Soochow University-Endocrinology
Suzhou, Jiangsu, 215006, China
-
The First Bethune hospital of Jilin University-Endocrinology
Changchun, Jilin, 130061, China
-
The First People's Hospital of Changde City-Endocrinology
Changde, Hunan, 415003, China
-
The First People's Hospital of Changzhou
Changzhou, Jiangsu, 213003, China
-
The First People's Hospital of Changzhou
Changzhou, Jiangsu, 213004, China
-
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, 210011, China
-
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450003, China
-
The Second Affiliated Hospital of Zhengzhou University-Endocrinology
Zhengzhou, Henan, 450003, China
-
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050000, China
-
The Second Hospital of Hebei Medical University-Endocrinology
Shijiazhuang, Hebei, 050000, China
-
The Second Hospital of Tianjin Medical University
Tianjin, Tianjin Municipality, 300211, China
-
The first hospital of Jilin University
Changchun, Jilin, 130021, China
-
Tongren Hospital Shanghai Jiao Tong Univ. School of Medicine
Shanghai, Shanghai Municipality, 200336, China
-
Tongren Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200336, China